Related references
Note: Only part of the references are listed.Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
Haibo Zhang et al.
INTENSIVE CARE MEDICINE (2020)
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
Francesco Ferrara et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Juan Meng et al.
EMERGING MICROBES & INFECTIONS (2020)
Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
Ali Nehme et al.
HYPERTENSION RESEARCH (2017)
Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy
Michael Bader
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients
S Keidar et al.
CIRCULATION RESEARCH (2005)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)
Share Paper
